Veliparib

Generic Name: Veliparib

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₆N_₄O

CAS Number: 912444-00-9

Unique Ingredient Identifier: 01O4K0631N

Indication: 与化疗药物紫杉醇和卡铂联合用于治疗乳腺癌。

Clinical Trials

A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors

Phase 1

Completed

Conditions: BRCA Mutated
Oncology
BRCA Mutated Breast Cancer
High Grade Serous Ovarian Cancer

Interventions: Drug: Veliparib

First Posted Date: 2013-05-15

Last Posted Date: 2017-11-21

Lead Sponsor: AbbVie

Target Recruit Count: 71

Registration Number: NCT01853306

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

Phase 2

Completed

Conditions: Advanced Malignant Solid Neoplasm

Interventions: Drug: Temozolomide
Drug: Adavosertib
Drug: Everolimus
Drug: Trametinib
Drug: Veliparib
Drug: Carboplatin

First Posted Date: 2013-04-09

Last Posted Date: 2023-09-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 208

Registration Number: NCT01827384

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States

and more 5 locations

Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer

Phase 2

Completed

Conditions: HER2-negative Breast Cancer
Stage II Breast Cancer
Stage IIIC Breast Cancer
Triple-negative Breast Cancer
Estrogen Receptor-negative Breast Cancer
Stage IIIA Breast Cancer
Progesterone Receptor-negative Breast Cancer
Stage IIIB Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Veliparib

First Posted Date: 2013-03-26

Last Posted Date: 2025-04-30

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 9

Registration Number: NCT01818063

Locations: 🇺🇸
Walter Reed National Military Medical Center, Bethesda, Maryland, United States
🇺🇸
Reading Hospital, Reading, Pennsylvania, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Phase 1

Completed

Conditions: Stage IV Ovarian Cancer AJCC v6 and v7
Stage IV Primary Peritoneal Cancer AJCC v7
Stage IV Fallopian Tube Cancer AJCC v6 and v7

Interventions: Drug: Floxuridine
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Veliparib

First Posted Date: 2012-12-13

Last Posted Date: 2020-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 29

Registration Number: NCT01749397

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸
Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States

and more 2 locations

Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer

Phase 1

Completed

Conditions: Stage IVA Oropharyngeal Carcinoma AJCC v7
Stage IVB Oropharyngeal Carcinoma AJCC v7
Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Carboplatin
Drug: Cisplatin
Drug: Fluorouracil
Drug: Hydroxyurea
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Other: Placebo Administration
Radiation: Radiation Therapy
Drug: Veliparib

First Posted Date: 2012-10-22

Last Posted Date: 2023-06-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT01711541

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States

and more 2 locations

Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status

Phase 1

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Veliparib
Drug: Topotecan

First Posted Date: 2012-09-24

Last Posted Date: 2015-06-10

Lead Sponsor: Vejle Hospital

Target Recruit Count: 22

Registration Number: NCT01690598

Locations: 🇩🇰
Department of Oncology, Vejle Hospital, Vejle, Denmark

Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Brain Metastases From Non-small Cell Lung Cancer

Interventions: Drug: Placebo
Drug: Veliparib
Radiation: Whole brain radiation therapy

First Posted Date: 2012-08-06

Last Posted Date: 2018-06-06

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 307

Registration Number: NCT01657799

Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer

Phase 1

Completed

Conditions: Extensive Stage Small Cell Lung Carcinoma
Large Cell Lung Carcinoma
Neuroendocrine Carcinoma
Small Cell Carcinoma
Stage IV Non-Small Cell Lung Cancer AJCC v7

Interventions: Drug: Cisplatin
Drug: Etoposide
Drug: Veliparib
Drug: Placebo

First Posted Date: 2012-07-17

Last Posted Date: 2023-05-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 156

Registration Number: NCT01642251

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Greenville Health System Cancer Institute-Easley, Easley, South Carolina, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

and more 423 locations

Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Recurrent Lung Small Cell Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Temozolomide
Other: Placebo Administration
Drug: Veliparib

First Posted Date: 2012-07-11

Last Posted Date: 2025-04-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 97

Registration Number: NCT01638546

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States

and more 11 locations

Pre-Operative Radiation and Veliparib for Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Radiation: Radiation
Procedure: Lumpectomy/Mastectomy
Drug: Veliparib

First Posted Date: 2012-06-13

Last Posted Date: 2024-05-22

Lead Sponsor: Richard Zellars

Target Recruit Count: 19

Registration Number: NCT01618357

Locations: 🇺🇸
I U Health West, Avon, Indiana, United States
🇺🇸
Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Indiana University Health Methodist Hospital, Indianapolis, Indiana, United States

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy